Navigation Links
Omeros Announces Clinical Development Programs for OMS103HP and OMS302
Date:5/19/2011

utcomes measure used in the successful Phase 2 meniscectomy trial.

OMS302 will be evaluated for safety and efficacy in patients undergoing intra-ocular lens replacement surgery. The trials will enroll both cataract surgery and refractive lens exchange patients. This clinical program will involve two randomized, double-blind, placebo-controlled, multicenter trials. The first trial will be conducted in North America and data are expected in the first half of 2012.  Omeros will initiate the second trial in Europe following discussions with regulators to ensure that data collected meet European expectations for marketing approval. The co-primary endpoints for these trials – maintenance of intraoperative pupil dilation (mydriasis) and reduction of postoperative pain – are the same as those achieved in the recently completed 221-patient Phase 2b trial.

Omeros' OMS103HP Program

OMS103HP is Omeros' PharmacoSurgery™ product candidate being developed for use during arthroscopic procedures, including partial meniscectomy surgery, and was designed to provide a multimodal approach to preemptively block the inflammatory cascade induced by arthroscopy. OMS103HP is a proprietary combination of anti-inflammatory/analgesic active pharmaceutical ingredients (APIs), each with well-known safety and pharmacologic profiles. Each of the APIs are components of generic, FDA-approved drugs that have been marketed in the United States as over-the-counter or prescription drug products for over 15 years and have established and well-characterized safety profiles.

In a Phase 2 clinical trial that evaluated OMS103HP in patients undergoing partial meniscectomy surgery, OMS103HP provided clinically meaningful and significantly greater efficacy than vehicle as measured by patient-reported functional scores using the Knee Injury and Osteoarthritis Outcome Score (KOOS), passive knee flexion and visual analog scale pain scores. The patient-
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omeros Corporation Reports First Quarter 2011 Financial Results
2. Omeros Announces Expansion of Potential Indications for PDE7 Inhibitors
3. Omeros Announces Publication of MASP-2 Data in Proceedings of the National Academy of Sciences
4. Omeros Reports Outcome of Phase 3 Trials of OMS103HP
5. Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results
6. Omeros Unlocks Orphan GPCRs Linked to Pancreatic Cancer and Cognitive Disorders
7. Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo
8. Omeros Announces Publication of Data From Antifibrinolytic Program
9. Omeros Licenses Novel Antifibrinolytic Agents
10. Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy
11. Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 "Copay ... inflate sales of brand drugs among patients with ... according to a new report  from the ... of the Inspector General (OIG). Federal anti-kickback laws prohibit ... that are subsidized by the federal government. ...
(Date:9/19/2014)... Today, iHealth Lab Inc. announced it has secured ... its first institutional round of funding. The strategic investment ... accelerate growth and innovation, and invest in additional sales ... Ventures will join iHealth,s board of directors, bringing added ... "We are very pleased to have Xiaomi ...
(Date:9/19/2014)... LUBBOCK, Texas , Sept. 19, 2014 Kiromic, ... today the addition of Kent Hance , the former ... vice chairman. Hance retired as chancellor in July 2014, after ... pleased to announce that Kent Hance , the most ... joined the Kiromic team not only as an investor, but ...
Breaking Medicine Technology:PCMA: New OIG Report Cites Drug Manufacturer "Copay Coupon" Use in Medicare Part D 2iHealth Raises $25 Million to Fuel Growth and Global Market Share 2Former Texas Tech Chancellor Named New Vice Chairman of the Board of Kiromic, LLC 2
... Feb. 20, 2011 NxStage® Medical, Inc. ... innovative dialysis products, today announced the latest interim results ... in overall quality of life benefits, significant improvement in ... Legs Syndrome (RLS) symptoms experienced by patients after 12 ...
... One year to the day of its introduction, the ... to its official company launch.  "Starting a new company takes ... about the industry and our place in it and now ... healthcare." Dr. McCord is no stranger to healthcare. ...
Cached Medicine Technology:New NxStage® FREEDOM Data Shows Continued, Marked Benefits for Patients Using the System One™ for Daily Home Hemodialysis Throughout a 12 Month Period 2New NxStage® FREEDOM Data Shows Continued, Marked Benefits for Patients Using the System One™ for Daily Home Hemodialysis Throughout a 12 Month Period 3New NxStage® FREEDOM Data Shows Continued, Marked Benefits for Patients Using the System One™ for Daily Home Hemodialysis Throughout a 12 Month Period 4
(Date:9/21/2014)... York (PRWEB) September 21, 2014 ... their Risk Management Portal designed for Diocesan risks. ... the intent to support effective risk management and ... to go live coinciding with Waldorf’s exhibition at ... 2014. , These applications were developed in collaboration ...
(Date:9/21/2014)... Texas (PRWEB) September 22, 2014 ... the past decade, as it has become saturated ... beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and ... also been facing increasing generic competition. However, the ... once-daily ICS and ICS/LABA therapies delivered by the ...
(Date:9/21/2014)... "I want to help people who are having ... money for chiropractors," said an inventor from St. Amat, ... for myself." , The Stretch is a device that ... and align the spine properly. It improves flexibility and ... nerves. Compact and easy to use, it's ideal for ...
(Date:9/21/2014)... 2014 (HealthDay News) -- Young women starting college understand ... foods they should eat. But they aren,t confident they ... to a new study. The study involved ... Illinois,s Peer Education Exercising and Eating Right program. The ... choose to eat if they were very busy with ...
(Date:9/21/2014)... 2014 Originally approved by the ... Flovent (fluticasone propionate) is a synthetic ICS therapy ... the maintenance treatment of asthma prophylactically in children ... formulations, Diskus and HFA, which received the FDA ... ingredient, fluticasone propionate, can bind to glucocorticoid receptors ...
Breaking Medicine News(10 mins):Health News:Waldorf Risk Solutions Releases New Risk Management Portal 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News: College Women Can Use Food Strategies, Study Finds 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4
... WellPoint, Inc. (NYSE: WLP ) announced ... New York Attorney General regarding the manner in which ... terms of the Agreement with the Attorney General, WellPoint ... database, which it uses in determining out-of-network reimbursement for ...
... RI Researchers at Rhode Island Hospital have completed ... control measures during a possible flu pandemic. Their study ... from individuals showing no symptoms (asymptomatic) or from individuals ... The researchers call on the scientific community to ...
... LOUISVILLE, Ky., Feb. 18 Almost Family, Inc. (Nasdaq: ... nursing services, announced today that it will be added to ... on Friday, February 20, 2009.William Yarmuth, President and CEO of ... included in the S&P SmallCap 600 Index, as it adds ...
... Taking Control of Your Diabetes,(TCOYD) announced findings ... firm Yankelovich that found that more than one ... that excess weight has a positive effect on,the ... often contributes,to the development of diabetes, complicates proper ...
... love their meat. Whether it,s rib eyes, pork chops or ... this country that more than 85 billion pounds of meat ... About a quarter of U.S. beef and pork is exported ... now the world,s largest consumer of meat, in Mexico, meat ...
... Spanish . , A team of specialists ... of genetic variants that have greater resistance to a specific ... some child patients affected by osteosarcoma. The team investigated the ... therapeutic treatment in the future. , In concrete, the research ...
Cached Medicine News:Health News:WellPoint Joins New York Attorney General in Creation of New Independent Database for Out-of-Network Reimbursement 2Health News:Study calls for increased research in flu transmission to prepare for pandemic flu outbreak 2Health News:Almost Family to be Added to the S&P SmallCap 600 Index 2Health News:One in Five Augustans With Type 2 Diabetes Mistakenly Believe That Being Obese or Overweight Can Positively Impact Their Disease 2Health News:One in Five Augustans With Type 2 Diabetes Mistakenly Believe That Being Obese or Overweight Can Positively Impact Their Disease 3Health News:American Veterinary Medical Association: Weaving a Web for Food Safety 2Health News:Research increases possibilities of personalizing treatment of infant osteosarcoma 2Health News:Research increases possibilities of personalizing treatment of infant osteosarcoma 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: